Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661897 | 1.00 | NPC1 (0.33) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL1660866 | 0.88 | — | — | |
| SCHEMBL16513728 | 0.84 | NPC1 (0.33) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL1660333 | 0.84 | CA2 (0.39) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL1661082 | 0.82 | CA2 (0.38) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL1660874 | 0.82 | NPC1 (0.35) | NPC1MEN1KMT2A | |
| SCHEMBL278866 | 0.82 | CA2 (0.37) | NPC1CA2CHKALMNARAB9A | |
| SCHEMBL16532258 | 0.80 | CA2 (0.36) | NPC1MEN1KMT2ACA2CHKA | |
| SCHEMBL16513889 | 0.79 | NPC1 (0.30) | NPC1 | |
| SCHEMBL22065025 | 0.79 | NPC1 (0.30) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-115989235-A | Methods of treating respiratory diseases using amino acid compounds | 普利安特治疗公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4146264-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022232838-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-3952902-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |